Role of histone deacetylases and their inhibitors in neurological diseases.
4-phenylbutyric acid (PBA) (Pubchem CID:4775)
5-Cinnamic acid (CNA)(Pubchem CID:444539)
Alzheimer’s disease
Belinostat (Pubchem CID:6918638)
Benzamide(Pubchem CID:2331)
Chidamide(Pubchem CID:9800555)
Entinostat(Pubchem CID:4261)
Givinostat/Duvyzat(Pubchem CID:9804992)
Huntington’s disease
LMK235(Pubchem CID:71520717)
MC1568(Pubchem CID:11381449)
Panobinostat(Pubchem CID:6918837)
Panobinostat(Pubchem CID:6918837).
Parkinson’s disease
Romidepsin(Pubchem CID:5352062)
Sodium butyrate(Pubchem CID:5222465)
Sodium phenylbutyrate(Pubchem CID:5258)
Trichostatin A(Pubchem CID:444732)
Ursodeoxycholic acid taurine(AMX0035)(Pubchem CID:129316491)
Valproic acid(Pubchem CID:3121)
Venlafaxine(Pubchem CID:5656)
Vorinostat(Pubchem CID:5311)
histone deacetylase
histone deacetylase inhibitors
neurological disease
Journal
Pharmacological research
ISSN: 1096-1186
Titre abrégé: Pharmacol Res
Pays: Netherlands
ID NLM: 8907422
Informations de publication
Date de publication:
12 Sep 2024
12 Sep 2024
Historique:
received:
16
05
2024
revised:
05
09
2024
accepted:
10
09
2024
medline:
15
9
2024
pubmed:
15
9
2024
entrez:
14
9
2024
Statut:
aheadofprint
Résumé
Histone deacetylases (HDACs) are zinc-dependent deacetylases that remove acetyl groups from lysine residues of histones or form protein complexes with other proteins for transcriptional repression, changing chromatin structure tightness, and inhibiting gene expression. Recent in vivo and in vitro studies have amply demonstrated the critical role of HDACs in the cell biology of the nervous system during both physiological and pathological processes and have provided new insights into the conduct of research on neurological disease targets. In addition, in vitro and in vivo studies on HDAC inhibitors show promise for the treatment of various diseases. This review summarizes the regulatory mechanisms of HDAC and the important role of its downstream targets in nervous system diseases, and summarizes the therapeutic mechanisms and efficacy of HDAC inhibitors in various nervous system diseases. Additionally, the current pharmacological situation, problems, and developmental prospects of HDAC inhibitors are described. A better understanding of the pathogenic mechanisms of HDACs in the nervous system may reveal new targets for therapeutic interventions in diseases and help to relieve healthcare pressure through preventive measures.
Identifiants
pubmed: 39276955
pii: S1043-6618(24)00355-4
doi: 10.1016/j.phrs.2024.107410
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
107410Informations de copyright
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Declaration of interest The authors declare that they have no competing interests.